盛国平，树兰（杭州）医院，感染科，主任医师，浙江大学硕士生导师，树兰（杭州）医院副院长，兼医务部主任，感染科副主任，体重管理中心主任。协会兼职：中国医师协会理事，中国医师协会感染科医师分会常委，中华预防医学会微生态分会委员，浙江省社会办医协会秘书长兼驻会副会长，浙江省医师协会副秘书长，浙江省医学会感染病学分会常委，浙江省抗痨协会委员，世界华人医师协会理事。从事临床、科研和教学工作20年，对各类急慢性肝损伤、肝硬化以及细菌、病毒、真菌等感染性疾病的诊治有丰富的经验。并主持国家十一五、十二五重大传染病专项子课题，国家新发突发传染病诊治专项子课题、浙江省创新团队子课题、国家重点研发项目《主动健康和老龄化科技应对——“微生态影响机体健康的机制研究”》子课题《肠道微生态变化与肠-肝轴衰老的关系与机制研究》和《突发急性和烈性传染病临床救治关键技术研究》子任务《重要院内感染耐药菌临床防控技术研究》等课题。在重症感染领域，负责感染科重症感染以及感染监护室的管理工作，接诊呼吸道、腹腔、血流、颅内、皮肤软组织等部位的感染，尤其是耐药菌和复杂感染的诊治工作。针对耐药菌，课题组创新型应用抗菌肽联合纳米材料进行抗感染治疗，对局部感染和肠道感染的诊治具有转化价值。通过多中心艰难梭菌等耐药菌的防治管理，建立了以医生为核心的多学科协同防控方案，对高危人群的筛查，并利用微生态调节治疗、抗感染药物选择、工勤人员终末消毒、护理团队的院内感染监察等工作，为我国耐药菌建立完整的流行病学数据，并制定完善的治疗方案，全面提升我国难辨梭菌的防治能力。参与了《临床重要耐药菌感染传播防控策略专家共识》、《中国微生态调节剂临床应用专家共识 2020版》、《人工肝血液净化系统应用于重型新型冠状病毒肺炎治疗的专家共识》等专家共识的编写工作。在外内外期刊发表论文30余篇。

Guoping Sheng，Chief Physician, Department of Infectious Diseases, Shulan (Hangzhou) Hospital，Master's Supervisor, Zhejiang University，Vice President of Shulan (Hangzhou) Hospital，Concurrent Director of Medical Affairs Department, Deputy Director of Department of Infectious Diseases, and Director of Weight Management Center

Professional Affiliations：

Director, Chinese Medical Doctor Association

Standing Committee Member, Infectious Diseases Physicians Branch of Chinese Medical Doctor Association

Committee Member, Microecology Branch of Chinese Preventive Medicine Association

Secretary-General and Resident Vice President, Zhejiang Social Medical Association

Deputy Secretary-General, Zhejiang Medical Doctor Association

Standing Committee Member, Infectious Diseases Branch of Zhejiang Medical Association

Committee Member, Zhejiang Anti-Tuberculosis Association

Director, World Association of Chinese Physicians

Professional Experience & Expertise：

With 20 years of experience in clinical practice, scientific research, and teaching, he has extensive expertise in diagnosing and treating various acute and chronic liver injuries, liver cirrhosis, and infectious diseases caused by bacteria, viruses, fungi, etc. He has presided over multiple key research projects, including sub-projects of the National Eleventh and Twelfth Five-Year Plans for Major Infectious Diseases, sub-projects of the National Special Project for Diagnosis and Treatment of Emerging and Sudden Infectious Diseases, sub-projects of Zhejiang Provincial Innovation Team, and sub-projects under the National Key R&D Program: "Mechanism Research on Microecology Affecting Body Health" (focusing on the relationship and mechanism between intestinal microecological changes and gut-liver axis aging) and "Key Clinical Treatment Technologies for Emerging Acute and Virulent Infectious Diseases" (focusing on clinical prevention and control technologies for important drug-resistant nosocomial infections).

In the field of severe infections, he is responsible for the management of severe infectious cases in the Department of Infectious Diseases and the Infection Intensive Care Unit. He diagnoses and treats infections in the respiratory tract, abdominal cavity, bloodstream, intracranial region, skin and soft tissues, with a particular focus on drug-resistant bacteria and complex infections.

For drug-resistant bacteria, his research team innovatively applies antimicrobial peptides combined with nanomaterials for anti-infective treatment, which has translational value in the diagnosis and treatment of local and intestinal infections. Through multi-center management of prevention and treatment of drug-resistant bacteria such as Clostridium difficile, he has established a doctor-led multi-disciplinary collaborative prevention and control program. This includes screening of high-risk groups, microecological regulation therapy, rational selection of anti-infective drugs, terminal disinfection by logistics staff, and nosocomial infection monitoring by nursing teams. These efforts have helped establish comprehensive epidemiological data and improved treatment protocols for drug-resistant bacteria in China, significantly enhancing the country's capacity for Clostridium difficile prevention and control.He has participated in the compilation of several expert consensuses, including "Expert Consensus on Prevention and Control Strategies for Transmission of Clinically Important Drug-Resistant Bacterial Infections", "Expert Consensus on Clinical Application of Microecological Modulators in China (2020 Edition)", and "Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe Coronavirus Disease 2019". He has published more than 30 papers in domestic and international journals.